Aurinia Pharmaceuticals Inc. has announced its financial results for the third quarter of 2026, showcasing significant growth in revenue and net income. This update is crucial for the company as it reflects its ongoing success in the pharmaceutical sector, particularly with its leading product, LUPKYNIS.

On October 30, 2026, Aurinia reported total revenue of $83.7 million for the three months ended September 30, 2026, marking a 14% increase from $73.5 million in the same period of 2025. The nine-month revenue also saw a rise of 19%, reaching $244.6 million compared to $205.9 million in the previous year.

The company, which operates under the SIC code 2834 for Pharmaceutical Preparations, is publicly traded on the Nasdaq under the ticker AUPH. Aurinia has been actively filing reports, with the most recent being this 8-K detailing its financial results.

According to the filing, net product sales of LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, amounted to $79.4 million for the quarter, up 12% from $70.6 million in Q3 2025. For the nine months, net product sales reached $232.4 million, an 18% increase from $197.2 million in the same period last year.

The filing also highlighted a substantial increase in license, collaboration, and royalty revenue, which rose by 54% for the quarter and 39% for the nine months, amounting to $4.3 million and $12.2 million, respectively. This growth is indicative of Aurinia's expanding partnerships and market presence.

Net income before taxes for the quarter was reported at $38.7 million, a 21% increase from $32.0 million in Q3 2025. For the nine months, net income reached $131.4 million, which is a remarkable 67% increase compared to $78.5 million in the same period last year. The net income for the quarter was slightly flat at $31.7 million, compared to $31.6 million in 2025, but for the nine months, it increased by 35% from $76.4 million.

In terms of earnings per share, Aurinia reported diluted earnings of $0.23 for the quarter, unchanged from the previous year, while for the nine months, it increased to $0.76 from $0.55.

Aurinia's cash position also strengthened, with cash, cash equivalents, and investments totaling $486.9 million as of September 30, 2026, compared to $398.0 million at the end of 2025. The company reported cash flows from operating activities of $46.4 million for the quarter, up 4% from the previous year.

Looking ahead, Aurinia has raised its total revenue guidance for 2026 from a range of $315 million to $325 million, now estimating between $325 million and $330 million. The net product sales guidance has been narrowed to a range of $310 million to $315 million.

Aurinia is also making strides in clinical development, having initiated the PRESERVE study, a Phase 4 trial investigating the combination of LUPKYNIS with other therapies for lupus nephritis. This study aims to enroll approximately 150 patients across 50 sites in the U.S., highlighting Aurinia's commitment to advancing treatment options in the autoimmune disease space.

The filing does not specify what actions will follow this report, but the strong financial performance and positive guidance suggest that Aurinia Pharmaceuticals is well-positioned for continued growth in the pharmaceutical industry.